FY2024 Earnings Estimate for Genelux Issued By HC Wainwright

Genelux Co. (NASDAQ:GNLX) – Equities researchers at HC Wainwright raised their FY2024 earnings per share estimates for shares of Genelux in a research report issued on Tuesday, March 25th. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings of ($0.84) per share for the year, up from their prior estimate of ($0.88). HC Wainwright currently has a “Buy” rating and a $30.00 price target on the stock. The consensus estimate for Genelux’s current full-year earnings is ($0.88) per share. HC Wainwright also issued estimates for Genelux’s Q4 2024 earnings at ($0.14) EPS, FY2025 earnings at ($0.72) EPS, FY2026 earnings at ($0.84) EPS, FY2027 earnings at ($0.07) EPS and FY2028 earnings at $1.23 EPS.

Genelux (NASDAQ:GNLX) last announced its quarterly earnings data on Friday, April 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.07).

Genelux Stock Performance

Shares of GNLX stock opened at $3.08 on Thursday. The stock has a fifty day simple moving average of $4.06 and a two-hundred day simple moving average of $3.10. The firm has a market capitalization of $106.38 million, a PE ratio of -3.24 and a beta of -1.41. Genelux has a 52-week low of $1.60 and a 52-week high of $6.50.

Institutional Trading of Genelux

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. XTX Topco Ltd purchased a new stake in Genelux during the 3rd quarter valued at approximately $59,000. Geode Capital Management LLC boosted its position in shares of Genelux by 39.7% during the third quarter. Geode Capital Management LLC now owns 316,160 shares of the company’s stock worth $749,000 after acquiring an additional 89,854 shares during the last quarter. Apollon Wealth Management LLC grew its stake in Genelux by 20.4% during the fourth quarter. Apollon Wealth Management LLC now owns 16,863 shares of the company’s stock valued at $40,000 after acquiring an additional 2,857 shares in the last quarter. D.A. Davidson & CO. bought a new stake in Genelux in the 4th quarter valued at $51,000. Finally, LifeSteps Financial Inc. lifted its stake in Genelux by 11.1% in the 4th quarter. LifeSteps Financial Inc. now owns 86,970 shares of the company’s stock worth $205,000 after purchasing an additional 8,715 shares in the last quarter. Institutional investors own 37.33% of the company’s stock.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.